モノクローナル抗体（mABs）治療薬市場：製造方法（in-Vitro、in-Vivo）、供給源（ヒト、キメラ）、投与経路（静脈内、皮下）、治療法（炎症・自己免疫、腫瘍、血液）別 - 2029年までの世界予測

Monoclonal Antibody (mABs) Therapeutics Market by Production Method (In-Vitro, In-Vivo), Sources (Human, Chimeric), Route of Administration (Intravenous, Subcutaneous), Therapy (Inflammatory & Autoimmune, Oncology, Hematology) - Global Forecast to 2029

モノクローナル抗体治療薬市場は、2024年の推定2,526億米ドルから2029年には4,975億米ドルに達すると予測され、予測期間中の年平均成長率は14.5%である。モノクローナル抗体治療薬市場の推進要因としては、慢性... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
MarketsandMarkets マーケッツアンドマーケッツ	2024年3月15日	US$4,950 シングルユーザライセンスライセンス・価格情報・注文方法はこちら	351	423	英語

日本語のページは自動翻訳を利用し作成しています。

サマリー

モノクローナル抗体治療薬市場は、2024年の推定2,526億米ドルから2029年には4,975億米ドルに達すると予測され、予測期間中の年平均成長率は14.5%である。
モノクローナル抗体治療薬市場の推進要因としては、慢性疾患の蔓延、バイオテクノロジーの進歩、標的治療に対する需要の高まりなどが挙げられる。例えば、リンパ腫治療薬のリツキサン（リツキシマブ）、自己免疫疾患治療薬のヒュミラ（アダリムマブ）、がん免疫療法薬のキイトルーダ（ペムブロリズマブ）などが挙げられ、その有効性と幅広い用途によって市場の成長を牽引している。
"2023年、製造方法別ではIn-Vitroセグメントが最大シェアを占める"
生産方法に基づき、モノクローナル抗体治療薬市場はin-vitroとin-vivoに区分される。2023年には、in-vitroセグメントがモノクローナル抗体治療薬市場を支配した。in-vitro生産法モノクローナル抗体治療薬市場の推進要因には、スケーラビリティ、費用対効果、バッチ間のばらつきの低減、規制遵守が含まれ、信頼性が高く一貫性のあるバイオ医薬品生産に対する需要を満たしている。
"2023年、ヒトセグメントが供給源別で最大のシェアを占める"
供給源に基づき、モノクローナル抗体治療薬市場はヒト、ヒト化、キメラ、その他の供給源に区分される。2023年にはヒト由来セグメントが市場を支配し、ヒト化セグメントは予測期間中に大きなCAGRで成長するとみられる。ヒトをソースとするモノクローナル抗体治療薬市場の推進要因には、非ヒトソースと比較して免疫原性が低減していること、有効性が向上していること、安全性プロファイルが改善されていることなどが挙げられる。さらに、ヒト化技術の進歩やヒトの免疫応答に対する理解の深まりは、多様な治療ニーズに対応し、この市場の成長に寄与している。
"2023年の治療領域別シェアは自己免疫・炎症性疾患領域が最大"
モノクローナル抗体治療薬市場は、自己免疫＆炎症性疾患、腫瘍学、血液学、眼科学、その他の治療領域に区分される。2023年には、自己免疫疾患と炎症性疾患がモノクローナル抗体治療薬市場を支配した。がん分野は、2024〜2029年の予測期間中に大きなCAGRで成長すると予測されている。癌モノクローナル抗体治療薬の高成長は、世界的な癌罹患率の増加、標的治療薬の受け入れ拡大が後押ししている。継続的な研究開発努力とバイオテクノロジーの進歩が、この分野の堅調な成長軌道に寄与している。

「2024〜2029年の予測期間中、モノクローナル抗体治療薬市場では欧州が最も高いCAGRで成長している。
北米がモノクローナル抗体治療薬市場を支配している。欧州は、有利な規制の枠組み、強固な医療インフラ、研究開発投資の増加、慢性疾患の有病率の上昇など、さまざまな要因により、年平均成長率が最も高くなる可能性が高い。これらの要素は総体的に、市場の拡大と技術革新に資する環境を醸成している。
本レポートのために実施した一次インタビューは以下のように分類できる：

- 回答者別供給側70％、需要側30
- 役職別管理職 - 45%、CXOおよび取締役 - 30%、経営幹部 - 25
- 地域別北米40％、欧州25％、アジア太平洋地域20％、中南米10％、中東・アフリカ5
レポート掲載企業リスト
- F.ホフマン・ラ・ロシュ社（スイス）
- アッヴィ社（米国）
- ジョンソン・エンド・ジョンソン・サービス社（米国）
- メルク・アンド・カンパニー・インク（米国）
- ブリストル・マイヤーズスクイブ・カンパニー（米国）
- アストラゼネカ（英国）
- サノフィ（フランス）
- ノバルティスAG（スイス）
- アムジェン社（米国）
- 武田薬品工業（日本）
- GSK plc.英国
- イーライリリー・アンド・カンパニー（米国）
- リジェネロン社（米）
- バイオジェン（米）
- UCB S.A.（ベルギー）
- ベーリンガーインゲルハイム・インターナショナルGmbH（ドイツ）
- Y-mAbsセラピューティクス社（米国）
- テバ・ファーマシューティカル・インダストリーズ社（イスラエル(イスラエル）、
- メルクKGaA（ドイツ）
- 協和キリン協和キリン(協和キリン株式会社（日本）
- Swedish Orphan Biovitrum AB（スウェーデン）
- ユナイテッド・セラピューティクス社（米国）
- セラテクノロジーズ（カナダ）
- インサイト（米国）
- サン・ファーマシューティカル・インダストリーズ社（インド(インド）
調査範囲
この調査レポートは、モノクローナル抗体治療薬市場を、製造方法（インビトロ、インビボ）、供給源（ヒト、ヒト化、キメラ、その他の供給源）、治療領域（自己免疫疾患＆炎症性疾患、腫瘍学、血液学、眼科学、その他の治療領域）、投与経路（静脈内、皮下、その他の投与経路）、エンドユーザー（病院、介護施設、その他のエンドユーザー）、地域別（北米、欧州、アジア太平洋地域、中南米、中東、アフリカ）に分類しています。本レポートでは、モノクローナル抗体治療薬市場の成長に影響を与える促進要因、課題、機会、動向などの主要要因に関する詳細情報を網羅しています。主要な業界プレイヤーを詳細に分析し、事業概要、製品/サービスポートフォリオ、提携、拡大、合意、買収などの主要戦略、モノクローナル抗体治療薬市場に関連する最近の動向に関する洞察を提供しています。本レポートでは、モノクローナル抗体治療薬市場のエコシステムにおけるトップ企業や今後の新興企業の競合分析もカバーしています。
レポート購入の主な利点
本レポートは、モノクローナル抗体治療薬市場全体とそのサブセグメントにおける収益数の最も近い概算値を提供することで、市場リーダー/新規参入者を支援します。また、ステークホルダーが競合状況をより良く理解し、自社のビジネスをより良く位置づけ、適切な市場参入戦略を立てるための洞察を深めるのにも役立ちます。本レポートは、関係者が市場の脈動を理解し、主要な市場促進要因、阻害要因、機会、課題に関する情報を提供することを可能にします。
本レポートは、以下のポイントに関する洞察を提供します：
- 市場の成長に影響を与える主要な促進要因（バイオテクノロジーと遺伝子工学の進歩、個別化医療に対する需要の増加、革新的なmAb治療薬の製品パイプラインの増加）、阻害要因（厳しい規制当局の承認プロセス、mAb治療薬の高コスト）、機会（革新的な治療適応症、抗体工学における技術進歩の高まり）、課題（mAbの生産コストの上昇）に関する分析。
- 製品開発/イノベーション：モノクローナル抗体治療薬市場の新製品に関する詳細な洞察
- 臨床試験：第III相および第II&III相臨床試験中の製品に関する詳細分析。
- 市場開発：有利な市場に関する包括的な情報 - 当レポートでは様々な地域の市場を分析しています。
- 市場の多様化：モノクローナル抗体治療薬市場における新製品/サービス、未開拓の地域、最近の開発、投資に関する網羅的な情報
- 競合評価： F. Hoffmann-La Roche Ltd（スイス）、Abbvie Inc.（米国）、Johnson & Johnson Services, Inc.（米国）、Merck & Co.(英国）、イーライリリー・アンド・カンパニー（米国）などがある。

ページTOPに戻る

1 INTRODUCTION 29
1.1 STUDY OBJECTIVES 29
1.2 MARKET DEFINITION 29
1.2.1 INCLUSIONS & EXCLUSIONS 29
1.3 MARKET SCOPE 30
1.3.1 MARKETS COVERED 30
1.3.2 YEARS CONSIDERED 31
1.3.3 CURRENCY CONSIDERED 31
1.4 RESEARCH LIMITATIONS 31
1.5 STAKEHOLDERS 32
1.6 RECESSION IMPACT 32
2 RESEARCH METHODOLOGY 33
2.1 RESEARCH DATA 33
FIGURE 1 RESEARCH DESIGN 33
2.1.1 SECONDARY DATA 34
2.1.2 PRIMARY DATA 35
FIGURE 2 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: BREAKDOWN OF PRIMARIES 35
2.2 MARKET SIZE ESTIMATION 36
FIGURE 3 MONOCLONAL ANTIBODY THERAPEUTICS: MARKET SIZE ESTIMATION (SUPPLY SIDE ANALYSIS), 2023 36
FIGURE 4 MONOCLONAL ANTIBODY THERAPEUTICS: MARKET SIZE ESTIMATION (PRODUCT-BASED ANALYSIS), 2023 37
FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2023 38
FIGURE 6 ILLUSTRATIVE EXAMPLE OF F. HOFFMANN-LA ROCHE AG: REVENUE SHARE ANALYSIS, 2023 38
2.2.1 INSIGHTS FROM PRIMARIES 40
FIGURE 7 MARKET VALIDATION FROM PRIMARY EXPERTS 40
2.2.2 SEGMENT ASSESSMENT (BY PRODUCTION METHOD, SOURCE, ROUTE OF ADMINISTRATION, THERAPY AREA, AND END USER) 40
FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 40
2.3 GROWTH RATE ASSUMPTIONS 41
FIGURE 9 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: CAGR PROJECTIONS, 2024–2029 42
FIGURE 10 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES 42
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 43
FIGURE 11 DATA TRIANGULATION METHODOLOGY 43
2.5 STUDY ASSUMPTIONS 44
2.6 RISK ANALYSIS 44
2.7 RECESSION IMPACT ANALYSIS 45
3 EXECUTIVE SUMMARY 46
FIGURE 12 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2024 VS. 2029 (USD MILLION) 46
FIGURE 13 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2024 VS. 2029 (USD MILLION) 47
FIGURE 14 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY TYPE, 2024 VS. 2029 (USD MILLION) 47
FIGURE 15 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION) 48
FIGURE 16 GEOGRAPHICAL SNAPSHOT OF MONOCLONAL ANTIBODY THERAPEUTICS MARKET 49
4 PREMIUM INSIGHTS 50
4.1 MONOCLONAL ANTIBODY THERAPEUTICS MARKET OVERVIEW 50
FIGURE 17 ADVANCEMENTS IN BIOTECHNOLOGY AND GENETIC ENGINEERING TO DRIVE MARKET DURING FORECAST PERIOD 50
4.2 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD (2023) 51
FIGURE 18 IN-VITRO PRODUCTION METHOD ACCOUNTED FOR LARGEST MARKET SHARE IN 2023 51
4.3 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2024 VS. 2029 (USD MILLION) 51
FIGURE 19 HUMAN SOURCE SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE DURING FORECAST PERIOD 51
4.4 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 52
FIGURE 20 GERMANY TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 52
5 MARKET OVERVIEW 53
5.1 INTRODUCTION 53
5.2 MARKET DYNAMICS 53
FIGURE 21 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 53
5.2.1 DRIVERS 54
5.2.1.1 Advancements in biotechnology and genetic engineering 54
5.2.1.2 Increasing demand for personalized medicine 55
5.2.1.3 Growing product pipeline of mAb therapeutics 55
FIGURE 22 NUMBER OF ANTIBODY THERAPEUTICS GRANTED FIRST APPROVAL IN US/EU (2012−2023) 56
5.2.2 RESTRAINTS 56
5.2.2.1 Stringent regulatory approval process 56
5.2.2.2 High cost of mAb treatments 57
5.2.3 OPPORTUNITIES 57
5.2.3.1 Innovative therapeutic indications 57
5.2.3.2 Rising technological advancements in antibody engineering 58

5.2.4 CHALLENGES 59
5.2.4.1 Rising development & production costs 59
5.3 PORTER’S FIVE FORCES ANALYSIS 59
TABLE 1 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 59
5.3.1 THREAT OF NEW ENTRANTS 59
5.3.2 THREAT OF SUBSTITUTES 60
5.3.3 BARGAINING POWER OF SUPPLIERS 60
5.3.4 BARGAINING POWER OF BUYERS 60
5.3.5 INTENSITY OF COMPETITIVE RIVALRY 60
5.4 TECHNOLOGY ANALYSIS 60
5.4.1 CONVENTIONAL PRODUCTION OF MABS 61
5.4.2 TECHNOLOGICAL ADVANCEMENTS FOR MABS 61
TABLE 2 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: TECHNOLOGY COMPARISON 62
5.5 VALUE CHAIN ANALYSIS 63
FIGURE 23 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: VALUE CHAIN 63
5.6 PATENT ANALYSIS 64
5.6.1 METHODOLOGY 64
5.6.2 PATENTS FILED BY DOCUMENT TYPE, 2014–2023 64
TABLE 3 PATENTS FILED, 2014–2023 64
5.6.3 INNOVATION AND PATENT APPLICATIONS 65
FIGURE 24 TOTAL NUMBER OF PATENTS GRANTED, 2014–2023 65
5.6.4 TOP APPLICANTS 65
FIGURE 25 TOP TEN PLAYERS WITH HIGHEST NUMBER OF PATENT APPLICATIONS, 2014–2023 65
FIGURE 26 REGIONAL ANALYSIS OF PATENTS GRANTED, 2014–2023 66
TABLE 4 TOP 10 PATENT OWNERS IN MONOCLONAL ANTIBODY THERAPEUTICS MARKET, 2013–2023 66
TABLE 5 PATENTS IN MONOCLONAL ANTIBODY THERAPEUTICS MARKET, 2023−2024 67
5.7 KEY CONFERENCES & EVENTS 68
TABLE 6 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: DETAILED LIST OF CONFERENCES & EVENTS (2024–2025) 68
5.8 INVESTMENT AND FUNDING SCENARIO 69
5.9 PIPELINE ANALYSIS 69
TABLE 7 MONOCLONAL ANTIBODY THERAPEUTICS IN CLINICAL PIPELINE 70
5.10 SUPPLY CHAIN ANALYSIS 77
FIGURE 27 MONOCLONAL ANTIBODY THERAPEUTICS MARKET: SUPPLY CHAIN ANALYSIS 78
5.11 ECOSYSTEM ANALYSIS 78
FIGURE 28 MONOCLONAL ANTIBODY THERAPEUTICS ECOSYSTEM 78
5.11.1 MONOCLONAL ANTIBODY THERAPEUTIC VENDORS 78
TABLE 8 MONOCLONAL ANTIBODY THERAPEUTIC VENDORS 79
5.11.2 END USERS OF MONOCLONAL ANTIBODY THERAPEUTICS 79
TABLE 9 MONOCLONAL ANTIBODY THERAPEUTIC END USERS 79
5.11.3 REGULATORY BODIES FOR MONOCLONAL ANTIBODY THERAPEUTICS 80
TABLE 10 MONOCLONAL ANTIBODY THERAPEUTIC REGULATORY BODIES 80
5.12 REGULATORY LANDSCAPE 80
5.12.1 REGULATORY ANALYSIS 80
5.12.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 81
TABLE 11 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 81
TABLE 12 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 81
TABLE 13 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 82
TABLE 14 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 82
5.13 PRICING ANALYSIS 83
5.13.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS 83
TABLE 15 AVERAGE SELLING PRICE OF MONOCLONAL ANTIBODY THERAPEUTICS IN US 83
5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 83
FIGURE 29 TECHNOLOGICAL ADVANCEMENTS IN MONOCLONAL ANTIBODY PRODUCTION TO DRIVE MARKET GROWTH 84
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA 85
5.15.1 KEY STAKEHOLDERS ON BUYING PROCESS 85
FIGURE 30 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR MABS AMONG TOP TWO END USERS 85
TABLE 16 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP TWO END USERS 85
5.15.2 BUYING CRITERIA FOR MONOCLONAL ANTIBODY THERAPEUTICS 86
FIGURE 31 KEY BUYING CRITERIA FOR HOSPITALS AND LONG-TERM CARE FACILITIES 86
TABLE 17 KEY BUYING CRITERIA FOR TOP TWO END USERS 86
6 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD 88
6.1 INTRODUCTION 89
TABLE 18 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION) 89
6.2 IN-VITRO PRODUCTION 89
6.2.1 HIGH SCALABILITY AND COST EFFICIENCY TO PROPEL MARKET 89
TABLE 19 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VITRO PRODUCTION, BY REGION, 2022–2029 (USD MILLION) 90
TABLE 20 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VITRO PRODUCTION, BY COUNTRY, 2022–2029 (USD MILLION) 90
TABLE 21 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VITRO PRODUCTION, BY COUNTRY, 2022–2029 (USD MILLION) 91
TABLE 22 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VITRO PRODUCTION, BY COUNTRY, 2022–2029 (USD MILLION) 91
TABLE 23 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VITRO PRODUCTION, BY COUNTRY, 2022–2029 (USD MILLION) 92
TABLE 24 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VITRO PRODUCTION, BY REGION, 2022–2029 (USD MILLION) 92
TABLE 25 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VITRO PRODUCTION, BY COUNTRY, 2022–2029 (USD MILLION) 92
6.3 IN-VIVO PRODUCTION 93
6.3.1 MINIMAL SIDE-EFFECTS TO SUPPORT MARKET GROWTH 93
TABLE 26 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VIVO PRODUCTION, BY REGION, 2022–2029 (USD MILLION) 93
TABLE 27 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VIVO PRODUCTION, BY COUNTRY, 2022–2029 (USD MILLION) 94
TABLE 28 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VIVO PRODUCTION, BY COUNTRY, 2022–2029 (USD MILLION) 94
TABLE 29 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VIVO PRODUCTION, BY COUNTRY, 2022–2029 (USD MILLION) 95
TABLE 30 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VIVO PRODUCTION, BY COUNTRY, 2022–2029 (USD MILLION) 95
TABLE 31 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VIVO PRODUCTION, BY REGION, 2022–2029 (USD MILLION) 96
TABLE 32 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR IN-VIVO PRODUCTION, BY COUNTRY, 2022–2029 (USD MILLION) 96
7 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION 97
7.1 INTRODUCTION 98
TABLE 33 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 98
7.2 INTRAVENOUS ROUTE OF ADMINISTRATION 98
7.2.1 DIRECT DELIVERY OF THERAPEUTIC DOSAGE FOR MULTIPLE INDICATIONS TO DRIVE MARKET 98
TABLE 34 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY REGION, 2022–2029 (USD MILLION) 99
TABLE 35 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 99
TABLE 36 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 100
TABLE 37 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 100
TABLE 38 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 101
TABLE 39 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY REGION, 2022–2029 (USD MILLION) 101
TABLE 40 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 101
7.3 SUBCUTANEOUS ROUTE OF ADMINISTRATION 102
7.3.1 ENHANCED PATIENT ADHERENCE AND LOW HEALTHCARE COSTS TO DRIVE MARKET 102
TABLE 41 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY REGION, 2022–2029 (USD MILLION) 103
TABLE 42 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 103
TABLE 43 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 104
TABLE 44 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 104
TABLE 45 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 105
TABLE 46 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY REGION, 2022−2029 USD MILLION) 105
TABLE 47 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 105
7.4 OTHER ROUTES OF ADMINISTRATION 106
TABLE 48 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2022–2029 (USD MILLION) 106
TABLE 49 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 107
TABLE 50 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 107
TABLE 51 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 108
TABLE 52 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 108
TABLE 53 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2022–2029 (USD MILLION) 109
TABLE 54 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER ROUTESC OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD MILLION) 109
8 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE 110
8.1 INTRODUCTION 111
TABLE 55 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 111
8.2 HUMAN SOURCE 111
8.2.1 REDUCED IMMUNOGENICITY AND IMPROVED EFFICACY TO PROPEL MARKET 111
TABLE 56 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCE, BY REGION, 2022–2029 (USD MILLION) 112
TABLE 57 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCE, BY COUNTRY, 2022–2029 (USD MILLION) 112
TABLE 58 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCE, BY COUNTRY, 2022–2029 (USD MILLION) 113
TABLE 59 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCE, BY COUNTRY, 2022–2029 (USD MILLION) 113
TABLE 60 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCE, BY COUNTRY, 2022–2029 (USD MILLION) 114
TABLE 61 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCE, BY REGION, 2022–2029 (USD MILLION) 114
TABLE 62 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMAN SOURCE, BY COUNTRY, 2022–2029 (USD MILLION) 114
8.3 HUMANIZED SOURCE 115
8.3.1 ABILITY TO ADJUST SPECIFICITY AND BIOLOGICAL FUNCTIONS TO DRIVE MARKET 115
TABLE 63 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCE, BY REGION, 2022–2029 (USD MILLION) 115
TABLE 64 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCE, BY COUNTRY, 2022–2029 (USD MILLION) 116
TABLE 65 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCE, BY COUNTRY, 2022–2029 (USD MILLION) 116
TABLE 66 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCE, BY COUNTRY, 2022–2029 (USD MILLION) 117
TABLE 67 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCE, BY COUNTRY, 2022–2029 (USD MILLION) 117
TABLE 68 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCE, BY REGION, 2022–2029 (USD MILLION) 118
TABLE 69 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HUMANIZED SOURCE, BY COUNTRY, 2022–2029 (USD MILLION) 118
8.4 CHIMERIC SOURCE 118
8.4.1 UTILIZATION OF GENETIC ENGINEERING TECHNIQUES FOR MINIMIZED IMMUNOGENIC RESPONSES TO FUEL MARKET 118
TABLE 70 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCE, BY REGION, 2022–2029 (USD MILLION) 119
TABLE 71 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCE, BY COUNTRY, 2022–2029 (USD MILLION) 119
TABLE 72 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCE, BY COUNTRY, 2022–2029 (USD MILLION) 120
TABLE 73 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCE, BY COUNTRY, 2022–2029 (USD MILLION) 120
TABLE 74 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCE, BY COUNTRY, 2022–2029 (USD MILLION) 121
TABLE 75 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCE, BY REGION, 2022–2029 (USD MILLION) 121
TABLE 76 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CHIMERIC SOURCE, BY COUNTRY, 2022–2029 (USD MILLION) 121
8.5 OTHER SOURCES 122
TABLE 77 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY REGION, 2022–2029 (USD MILLION) 122
TABLE 78 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY COUNTRY, 2022–2029 (USD MILLION) 123
TABLE 79 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY COUNTRY, 2022–2029 (USD MILLION) 123
TABLE 80 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY COUNTRY, 2022–2029 (USD MILLION) 124
TABLE 81 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY COUNTRY, 2022–2029 (USD MILLION) 124
TABLE 82 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY REGION, 2022–2029 (USD MILLION) 125
TABLE 83 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER SOURCES, BY COUNTRY, 2022–2029 (USD MILLION) 125
9 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA 126
9.1 INTRODUCTION 127
TABLE 84 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION) 127
9.2 INFLAMMATORY & AUTOIMMUNE DISORDERS 127
9.2.1 RISING DEMAND FOR TARGETED THERAPEUTICS TO DRIVE MARKET 127
TABLE 85 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISORDERS, BY REGION, 2022–2029 (USD MILLION) 128
TABLE 86 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 128
TABLE 87 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 129
TABLE 88 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 129
TABLE 89 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 130
TABLE 90 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISORDERS, BY REGION, 2022–2029 (USD MILLION) 130
TABLE 91 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISORDERS, BY COUNTRY, 2022–2029 (USD MILLION) 130
9.3 ONCOLOGY 131
9.3.1 GROWING FOCUS ON ONCOLOGY THERAPEUTICS TO PROPEL MARKET 131
TABLE 92 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CANCER, BY REGION, 2022–2029 (USD MILLION) 132
TABLE 93 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 132
TABLE 94 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 133
TABLE 95 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 133
TABLE 96 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION) 134
TABLE 97 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CANCER, BY REGION, 2022−2029 (USD MILLION) 134
TABLE 98 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR CANCER, BY COUNTRY, 2022−2029 (USD MILLION) 134

9.4 HEMATOLOGY 135
9.4.1 RISING INCIDENCE OF THROMBOTIC DISORDERS TO SUPPORT MARKET GROWTH 135
TABLE 99 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY REGION, 2022−2029 (USD MILLION) 135
TABLE 100 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2029 (USD MILLION) 136
TABLE 101 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022−2029 (USD MILLION) 136
TABLE 102 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2029 (USD MILLION) 137
TABLE 103 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2029 (USD MILLION) 137
TABLE 104 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY REGION, 2022–2029 (USD MILLION) 138
TABLE 105 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2029 (USD MILLION) 138
9.5 OPHTHALMOLOGY 138
9.5.1 RISING PREVALENCE OF AGE-RELATED MACULAR DEGENERATION TO BOOST DEMAND 138
TABLE 106 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OPHTHALMOLOGY, BY REGION, 2022–2029 (USD MILLION) 139
TABLE 107 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2022–2029 (USD MILLION) 139
TABLE 108 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2022–2029 (USD MILLION) 140
TABLE 109 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2022–2029 (USD MILLION) 140
TABLE 110 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2022–2029 (USD MILLION) 141
TABLE 111 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OPHTHALMOLOGY, BY REGION, 2022–2029 (USD MILLION) 141
TABLE 112 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2022–2029 (USD MILLION) 141
9.6 OTHER THERAPY AREAS 142
TABLE 113 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER THERAPY AREAS, BY REGION, 2022–2029 (USD MILLION) 143
TABLE 114 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022–2029 (USD MILLION) 143
TABLE 115 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022–2029 (USD MILLION) 144
TABLE 116 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022–2029 (USD MILLION) 144
TABLE 117 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022–2029 (USD MILLION) 145
TABLE 118 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER THERAPY AREAS, BY REGION, 2022–2029 (USD MILLION) 145
TABLE 119 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER THERAPY AREAS, BY COUNTRY, 2022–2029 (USD MILLION) 145
10 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER 146
10.1 INTRODUCTION 147
TABLE 120 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 147
10.2 HOSPITALS 147
10.2.1 AVAILABILITY OF ADVANCED HEALTHCARE INFRASTRUCTURE TO PROPEL MARKET 147
TABLE 121 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY REGION, 2022–2029 (USD MILLION) 148
TABLE 122 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION) 148
TABLE 123 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION) 149
TABLE 124 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION) 149
TABLE 125 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION) 150
TABLE 126 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY REGION, 2022–2029 (USD MILLION) 150
TABLE 127 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD MILLION) 150
10.3 LONG-TERM CARE FACILITIES 151
10.3.1 SPECIALIZED CARE AND CONTINUOUS MONITORING ADVANTAGES TO DRIVE MARKET 151
TABLE 128 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022–2029 (USD MILLION) 151
TABLE 129 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION) 152
TABLE 130 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION) 152
TABLE 131 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION) 153
TABLE 132 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION) 153
TABLE 133 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022–2029 (USD MILLION) 154
TABLE 134 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD MILLION) 154
10.4 OTHER END USERS 155
TABLE 135 MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY REGION, 2022–2029 (USD MILLION) 155
TABLE 136 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION) 155
TABLE 137 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION) 156
TABLE 138 ASIA PACIFIC: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION) 156
TABLE 139 LATIN AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION) 157
TABLE 140 MIDDLE EAST: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY REGION, 2022–2029 (USD MILLION) 157
TABLE 141 GCC COUNTRIES: MONOCLONAL ANTIBODY THERAPEUTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION) 157
11 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY REGION 158
11.1 INTRODUCTION 159
TABLE 142 MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY REGION, 2022–2029 (USD MILLION) 159
11.2 NORTH AMERICA 159
FIGURE 32 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET SNAPSHOT 160
TABLE 143 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 161
TABLE 144 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION) 161
TABLE 145 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 162
TABLE 146 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 162
TABLE 147 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION) 163
TABLE 148 NORTH AMERICA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 163
11.2.1 NORTH AMERICA: RECESSION IMPACT 164
11.2.2 US 164
11.2.2.1 Rising regulatory approvals for product commercialization to propel market 164
TABLE 149 PRODUCT APPROVALS FOR MAB THERAPEUTICS BY US FDA 165
TABLE 150 US: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION) 165
TABLE 151 US: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 166
TABLE 152 US: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 166
TABLE 153 US: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION) 167
TABLE 154 US: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 167
11.2.3 CANADA 167
11.2.3.1 Rising investments in antibody research to support market growth 167
TABLE 155 CANADA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION) 168
TABLE 156 CANADA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 168
TABLE 157 CANADA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 169
TABLE 158 CANADA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION) 169
TABLE 159 CANADA: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 170
11.3 EUROPE 170
FIGURE 33 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET SNAPSHOT 171
TABLE 160 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION) 172
TABLE 161 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION) 172
TABLE 162 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 173
TABLE 163 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 173
TABLE 164 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION) 174
TABLE 165 EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 174
11.3.1 EUROPE: RECESSION IMPACT 174
11.3.2 GERMANY 175
11.3.2.1 Rising number of clinical trials for mAb therapeutics to drive market 175
TABLE 166 GERMANY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION) 175
TABLE 167 GERMANY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 175
TABLE 168 GERMANY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 176
TABLE 169 GERMANY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION) 176
TABLE 170 GERMANY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 177
11.3.3 UK 177
11.3.3.1 Increasing R&D initiatives by pharmaceutical & biotechnology companies to support market growth 177
TABLE 171 UK: CANCER INCIDENCE, BY TYPE, 2020 VS. 2040 177
TABLE 172 UK: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION) 178
TABLE 173 UK: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 178
TABLE 174 UK: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 178
TABLE 175 UK: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION) 179
TABLE 176 UK: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 179
11.3.4 FRANCE 180
11.3.4.1 Favorable reimbursement policies for therapeutic treatments to propel market 180
TABLE 177 FRANCE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION) 180
TABLE 178 FRANCE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 180
TABLE 179 FRANCE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 181
TABLE 180 FRANCE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION) 181
TABLE 181 FRANCE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 182
11.3.5 ITALY 182
11.3.5.1 Growth in life sciences industry to boost demand 182
TABLE 182 ITALY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION) 182
TABLE 183 ITALY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 183
TABLE 184 ITALY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 183
TABLE 185 ITALY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION) 184
TABLE 186 ITALY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 184
11.3.6 SPAIN 185
11.3.6.1 Growing focus on research for biomaterial development to drive market 185
TABLE 187 SPAIN: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION) 185
TABLE 188 SPAIN: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 185
TABLE 189 SPAIN: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 186
TABLE 190 SPAIN: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION) 186
TABLE 191 SPAIN: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 187
11.3.7 TURKEY 187
11.3.7.1 Rising investments in R&D for healthcare infrastructure to support market growth 187
TABLE 192 TURKEY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION) 188
TABLE 193 TURKEY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 188
TABLE 194 TURKEY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 188
TABLE 195 TURKEY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION) 189
TABLE 196 TURKEY: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 189
11.3.8 REST OF EUROPE 190
TABLE 197 REST OF EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY PRODUCTION METHOD, 2022–2029 (USD MILLION) 190
TABLE 198 REST OF EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION) 190
TABLE 199 REST OF EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY SOURCE, 2022–2029 (USD MILLION) 191
TABLE 200 REST OF EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY THERAPY AREA, 2022–2029 (USD MILLION) 191
TABLE 201 REST OF EUROPE: MONOCLONAL ANTIBODY THERAPEUTICS MARKET, BY END USER, 2022–2029 (USD MILLION) 192

ページTOPに戻る

Table of Contents

Summary

The monoclonal antibody therapeutics market is projected to reach USD 497.5 billion by 2029 from an estimated USD 252.6 billion in 2024, at a CAGR of 14.5% during the forecast period.
The driving factors of the monoclonal antibody therapeutics market include increased prevalence of chronic diseases, advancements in biotechnology, and growing demand for targeted therapies. Examples include drugs like Rituxan (rituximab) for lymphoma, Humira (adalimumab) for autoimmune disorders, and Keytruda (pembrolizumab) for cancer immunotherapy, driving market growth through their effectiveness and broad applications.
“The In-Vitro segment accounted for the largest share by production method in 2023.”
Based on production method, the monoclonal antibody therapeutics market is segmented into in-vitro and in-vivo. In 2023, in-vitro segment dominated the monoclonal antibody therapeutics market. Driving factors of the in-vitro production method monoclonal antibody therapeutics market include scalability, cost-effectiveness, reduced batch-to-batch variability, and regulatory compliance, meeting demand for reliable and consistent biopharmaceutical production.
“The human segment accounted for the largest share by source in 2023.”
Based on source, the monoclonal antibody therapeutics market is segmented into human, humanized, chimeric and other sources. In 2023, human source segment dominated market and humanized segment is likely to grow at significant CAGR during the forecast period. The driving factors of the human source monoclonal antibody therapeutics market include reduced immunogenicity, enhanced efficacy, and improved safety profiles compared to non-human sources. Additionally, advancements in humanization techniques and increased understanding of human immune responses contribute to the growth of this market, catering to diverse therapeutic needs.
“The autoimmune & inflammatory disease segment accounted for the largest share by therapy area in 2023.”
The monoclonal antibody therapeutics market is segmented into autoimmune & inflammatory disorders, Oncology, Hematology, opthalmology and other therapy area. In 2023, autoimmune & inflammatory diseases dominated the monoclonal antibody therapeutics market. Cancer segment is anticipated to grow at significant CAGR during the forecast period of 2024-2029. The high growth cancer monoclonal antibody therapeutics is propelled by increasing incidences of cancer globally, coupled with growing acceptance of targeted therapies. Continuous research and development efforts, along with advancements in biotechnology, contribute to the robust growth trajectory of this segment.

““The Europe is growing at the highest CAGR in the monoclonal antibody therapeutics market during the forecast period of 2024-2029.”
North America dominates the monoclonal antibody therapeutics market. Europe, is likely to grow at highest CAGR owing to various factors such as favorable regulatory frameworks, robust healthcare infrastructure, increasing investment in research and development, and rising prevalence of chronic diseases. These elements collectively foster a conducive environment for market expansion and innovation.
The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70% and Demand Side 30%
• By Designation: Managers - 45%, CXOs and Directors - 30%, and Executives- 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, Middle East & Africa- 5%
List of Companies Profiled in the Report:
• F. Hoffmann-La Roche Ltd (Switzerland)
• Abbvie Inc. (US)
• Johnson & Johnson Services, Inc. (US)
• Merck & Co., Inc. (US)
• Bristol Myers Squibb Company (US)
• AstraZeneca (UK)
• Sanofi (France)
• Novartis AG (Switzerland)
• Amgen Inc. (US)
• Takeda Pharmaceutical Company Limited (Japan)
• GSK plc. (UK)
• Eli Lilly and Company (US)
• Regeneron Pharmaceuticals Inc. (US)
• Biogen (US)
• UCB S.A. (Belgium)
• Boehringer Ingelheim International GmbH (Germany)
• Y-mAbs Therapeutics Inc. (US)
• Teva Pharmaceutical Industries Ltd. (Israel),
• Merck KGaA (Germany)
• Kyowa Kirin Co. Ltd. (Japan)
• Swedish Orphan Biovitrum AB (Sweden)
• United Therapeutics Corporation (US)
• Theratechnologies Inc. (Canada)
• Incyte (US)
• Sun Pharmaceutical Industries Ltd. (India)
Research Coverage:
This research report categorizes the monoclonal antibody therapeutics market by production method (in-vitro and in-vivo), source (human, humanized, chimeric and other sources), therapy area (autoimmune & inflammatory disorders, Oncology, Hematology, opthalmology and other therapy area), route of administration (intravenous, subcutaneous and other route of administration), end user (hospitals, long-term care facilities, and other end user) and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, challenges, opportunities, and trends influencing the growth of the monoclonal antibody therapeutics market. A detailed analysis of the key industry players has been done to provide insights into their business overview, product/service portfolio, key strategies such as collaborations, partnerships, expansions, agreements, acquisitions, and recent developments associated with the monoclonal antibody therapeutics market. Competitive analysis of top players and upcoming startups in the monoclonal antibody therapeutics market ecosystem is covered in this report.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall monoclonal antibody therapeutics market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
• Analysis of key drivers (Advancements in biotechnology and genetic engineering, Increasing demand for personalized medicine, Growing product pipeline of innovative mAb therapeutics) restraints (Stringent regulatory approval process and High cost of mAb treatments), opportunities (Innovative therapeutic indications, Rising technological advancements in antibody engineering), and challenges (Rising production costs for mAbs) influencing the growth of the market.
• Product Development/Innovation: Detailed insights on newly launched products of the monoclonal antibody therapeutics market
• Clinical Trials: Detail Analysis on the products under clinical trials phase III and phase II&III.
• Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new products/services, untapped geographies, recent developments, and investments in the monoclonal antibody therapeutics market
• Competitive Assessment: are F. Hoffmann-La Roche Ltd (Switzerland), Abbvie Inc. (US), Johnson & Johnson Services, Inc. (US), Merck & Co., Inc. (US), Bristol Myers Squibb Company (US), AstraZeneca (UK), Sanofi (France), Novartis AG (Switzerland), Amgen Inc. (US), Takeda Pharmaceutical Company Limited (Japan), GSK plc. (UK), Eli Lilly and Company (US), among others in the market.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野の最新刊レポート

本レポートと同分野の最新刊レポートはありません。

MarketsandMarkets 社の最新刊レポート

本レポートと同じKEY WORD（）の最新刊レポート

本レポートと同じKEY WORDの最新刊レポートはありません。

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

モノクローナル抗体（mABs）治療薬市場：製造方法（in-Vitro、in-Vivo）、供給源（ヒト、キメラ）、投与経路（静脈内、皮下）、治療法（炎症・自己免疫、腫瘍、血液）別 - 2029年までの世界予測

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野の最新刊レポート

MarketsandMarkets 社の最新刊レポート

本レポートと同じKEY WORD（）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?